Supply Chain entity

Specialty Drugs

Product

All 1 tracked stories fall under one category: regulation. Donald Trump is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Specialty Drugs appears in 1 tracked Supply Chain story from September 30, 2026. The tracked stories average 2 original sources each.

Last mentioned: 2d ago

Entity pulse

Recent coverage · Specialty Drugs

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Specialty Drugs

All 1 tracked stories fall under one category: regulation. Donald Trump is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Specialty Drugs appears in 1 tracked Supply Chain story from September 30, 2026. The tracked stories average 2 original sources each.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Supply Chain stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Specialty Drugs. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Zero-rate list published, 100% tariff starts

    Commerce Department publishes Federal Register list of 20 zero-tariff countries for specialty drugs and ingredients; 100% tariff on other patented pharma imports becomes effective.

  2. Trump proclamation sets pharma tariffs

    President Donald Trump issues proclamation to impose tariffs on patented pharmaceuticals, biologics, and associated ingredients into the U.S. to encourage domestic production.

Stories mentioning Specialty Drugs 1

Trade Policy Positive

20 countries win zero tariff on specialty pharma; 100% hits others Sept 29

The US waives ad valorem tariffs on specialty drugs and components from 20 countries, including India, while a 100% tariff on patented pharma imports takes effect September 29. Supply chain teams must re-evaluate sourcing, country-of-origin classification, and customs exposure for rare disease, cell/gene, and ADC products.

2 sources

Specialty Drugs is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.